New Drug for Recurrent Glioblastoma (GBM)

What we are studying

The purpose of this study is to determine how much the study drug reaches the brain tumor. Study participants will take the study drug for 7 days before surgery. Once the study participant has recovered from the surgery, within 30 days they will start taking the drug again to see how they respond.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 90

Eligibility Criteria

  • Diagnosed with glioblastoma
  • Already received treatment with surgery; radiation and chemotherapy

What is involved

  • May receive study drug up to 7 days prior to surgery
  • Continue on study drug after surgery until tumor grows
  • Will be seen in clinic at routine visits

Compensation

None

Contact Information

Study Coordinator
Jill Weber
Email
jaweber@wakehealth.edu
Phone
336-713-3539

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.